The Role of PIK3CA in Cisplatin Resistance of Cervical Cancer

Date
2016
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Cervical cancer is a significant public health issue. A recent study (McIntyre et al; 2013) suggested that phosphatidyl inositol 3 kinase (PI3K) catalytic subunit α (PIK3CA) is an important marker for the prognosis of cervical cancer patients treated with chemoradiotherapy (CRT), with PIK3CA-mutant tumour bearing patients having poorer survival than PIK3CA-wt patients. Activating mutations in PIK3CA promote increased PI3K signalling, and tumorigenesis in vivo. I investigated the role that E545K, identified by McIntyre et al (2013) as the most common mutation in PIK3CA in cervical cancer, may play in radiation and cisplatin resistance of cervical cancer cell lines. This study indicated a potential role of PIK3CA in cisplatin resistance, although cisplatin resistance was not a universal characteristic of cells expressing PIK3CA-E545K, and was not reversed with the use of the PI3K inhibitor GDC-0941. The cisplatin resistant cell line showed sensitivity to GDC-0941, suggesting PI3K inhibitors as an alternative to cisplatin.
Description
Keywords
Biology--Cell, Biology--Molecular, Oncology
Citation
Merry, C. (2016). The Role of PIK3CA in Cisplatin Resistance of Cervical Cancer (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/28345